Nikkan Yakugyo Serial Planning "Toward the Era of Co-creation

<1>Industrial Policy Committee	Pharmaceuticals should be a growth market, with indicators and estimates. 　　Published in Nikkan Yakugyo, August 29, 2025 [License No. 20250829_01] Jiho Inc. has granted permission to use this article.
<2>Distribution Optimization Committee	Provision of information is "the responsibility of manufacturers and wholesalers. 　　Nikkan Yakugyo, September 1, 2025 [License No. 20250901_02] Jiho Co.
<3>Drug Evaluation Committee	Focusing on improving the clinical trial environment in Japan, the Pharmaceutical Manufacturers Association of Japan (PMAJ) and the Drug Evaluation Committee are considering international standards. 　　Nikkan Yakugyo, September 2, 2025 [License No. 20250902_02] Jiho Co.
4〉Pharmaceutical Affairs Committee	Alarmed by Extreme "No Need for Japanese P1," Kashiwatani, Chairperson of the Pharmaceutical Affairs Committee, Urges Proper Understanding of the Purpose 　　Nikkan Yakugyo September 3, 2025 [License No. 20250903_01] Jiho Co.
5〉Environmental Issues Committee	Greenhouse gases, broad-based rules to be formulated, Arima, Chairman of the Environmental Issues Study Committee 　　Nikkan Yakugyo September 4, 2025 [License No. 20250904_01] Jiho Co.
(6)ICH Project	ICH-PJ Chairman Yokota: "RWE can complement clinical trials," hopes for new topics 　　Nikkan Yakugyo September 5, 2025 [License No. 20250905_01] Jiho Co.
7〉Code Compliance Promotion Committee	Revised COP, "Focus on penetration of philosophy," Ouchi, Chairperson of Code and Compliance Promotion Committee 　　Nikkan Yakugyo September 8, 2025 [License No. 20250908_01] Jiho Co.
8〉Quality Committee	TF shares challenges in commercial production DX 　　Nikkan Yakugyo September 9, 2025 [License No. 20250910_06] Jiho Co.
(9)Public Relations Committee	Public Relations Committee Chair Tada Devises Information Dissemination Methods to Increase Understanding of the Pharmaceutical Industry 　　Nikkan Yakugyo September 10, 2025 [License No. 20250910_01] Jiho Co.
10〉Product Information Summary Review Committee	Planned training sessions with medical personnel to develop human resources Product Information Outline Review Committee, Chairman Kondo 　　Nikkan Yakugyo September 11, 2025 [License No. 20250911_01] Jiho Co.
11〉Pharmaceutical Consultation Committee	Guideline for handling RWE to be substantially revised this fall 　　Nikkan Yakugyo September 12, 2025 [License No. 20250912_01] Jiho Co.
12〉Patient Organization Coordination Committee	Patient and Citizen Involvement" to be compiled as a good practice example, Dr. Misawa, Chairperson of the Patient Groups Collaboration Promotion Committee 　　Nikkan Yakugyo September 13, 2025 [License No. 20250917_01] Jiho Co.
(13)Biopharmaceuticals Committee	Biopharmaceuticals Committee Chair Kurazaki Kurazaki, "We want to broaden the scope of human resource development in biotechnology. 　　Nikkan Yakugyo September 17, 2025 [License No. 20250917_02] Jiho Co.
Intellectual Property Committee	Intellectual Property Committee establishes TF to study issues in new fields such as AI. 　　Nikkan Yakugyo September 18, 2025 [License No. 20250919_02] Jiho Co.
(15)International Committee	International Committee Chairman Murakami strengthens communication to the international community and establishes a new organization. 　　Nikkan Yakugyo September 19, 2025 [License No. 20250919_03] Jiho Co.
Research and Development Committee	TPP outline released to help bridge the gap, R&D Committee Chairman Tsukahara 　　Nikkan Yakugyo September 20, 2025 [License No. 20250930_03] Jiho Co.
(17)Pharmaceutical Industry Policy Institute	Dr. Yamada, Director of Pharmaceutical Industry Policy Institute, contributes to the industry's consideration of issues through evidence 　　Nikkan Yakugyo, September 24, 2025 [License No. 20250930_04] Jiho Co.

TOP

Nikkan Yakugyo Serial Planning "Toward the Era of Co-creation

Site Search